Fibrostenosis Focused Therapeutics - RFP
The Crohn's and Colitis Foundation's Fibrostenosis Focused Therapeutics RFP funds translational research on non-surgical therapies for fibrosis in Crohn’s disease and ulcerative colitis.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (LOI) | August 14, 2026 (Full Proposal)
Funding Amounts: Up to $450,000 per project for one year; renewals possible if milestones are met; indirect costs capped at 10%.
Summary: Funds development of non-surgical, innovative therapeutics for fibrosis in IBD, targeting fibrostenosis in Crohn’s disease and ulcerative colitis.
Key Information: Preproposal required before LOI and full application; open to companies and academic groups with commercialization focus.
Description
This funding opportunity from the Crohn's and Colitis Foundation supports the development of innovative, non-surgical therapeutics addressing fibrosis (fibrostenosis) in inflammatory bowel disease (IBD), specifically Crohn’s disease and ulcerative colitis. The program seeks translational projects grounded in human clinical observations or published IBD evidence, with a focus on advancing product candidates—such as small molecules, biologics, gene or cell therapies, or novel devices (excluding surgical removal techniques)—to address this significant unmet clinical need. The initiative encourages multidisciplinary and collaborative approaches, particularly those that modulate specific fibrotic pathways and demonstrate commercialization potential.
